Visit-to-visit fasting plasma glucose variability is associated with left ventricular adverse remodeling in diabetic patients with STEMI.
Aged
Biomarkers
/ blood
Blood Glucose
/ metabolism
Diabetes Mellitus, Type 2
/ blood
Fasting
/ blood
Female
Humans
Male
Middle Aged
Percutaneous Coronary Intervention
/ adverse effects
Recurrence
Retrospective Studies
Risk Assessment
Risk Factors
ST Elevation Myocardial Infarction
/ diagnostic imaging
Time Factors
Treatment Outcome
Ventricular Function, Left
Ventricular Remodeling
FPG variability
Left ventricular adverse remodeling
ST-segment elevation myocardial infarction
Type 2 diabetes
Journal
Cardiovascular diabetology
ISSN: 1475-2840
Titre abrégé: Cardiovasc Diabetol
Pays: England
ID NLM: 101147637
Informations de publication
Date de publication:
02 09 2020
02 09 2020
Historique:
received:
01
06
2020
accepted:
29
08
2020
entrez:
4
9
2020
pubmed:
4
9
2020
medline:
18
5
2021
Statut:
epublish
Résumé
Patients with type 2 diabetes mellitus (T2DM) are predisposed to poor cardiovascular outcomes after ST-segment elevation myocardial infarction (STEMI). Left ventricular adverse remodeling (LVAR) triggered upon myocardial infarction is recognized as the predominant pathological process in the development of heart failure. In the present study, we sought to investigate whether visit-to-visit fasting plasma glucose (FPG) variability is a potential predictor of LVAR in T2DM patients after STEMI. From January 2014 to December 2018 in Ruijin Hospital, T2DM patients with STEMI who underwent primary percutaneous coronary intervention were consecutively enrolled and followed up for ~ 12 months. The changes in left ventricular geometric and functional parameters between baseline and 12-month follow-up were assessed by echocardiography. The incidence of LVAR, defined as 20% increase in indexed left ventricular end-diastolic volume (LVEDV), and its relationship with visit-to-visit FPG variability were analyzed. Multivariate regression models were constructed to test the predictive value of FPG variability for post-infarction LVAR. A total of 437 patients with type 2 diabetes and STEMI were included in the final analysis. During a mean follow-up of 12.4 ± 1.1 months, the incidence of LVAR was 20.6% and mean enlargement of indexed LVEDV was 3.31 ± 14.4 mL/m This study suggests that visit-to-visit FPG variability is an independent predictor of incidence of LVAR in T2DM patients with STEMI. Trial registration Trials number, NCT02089360; registered on March 17,2014.
Sections du résumé
BACKGROUND
Patients with type 2 diabetes mellitus (T2DM) are predisposed to poor cardiovascular outcomes after ST-segment elevation myocardial infarction (STEMI). Left ventricular adverse remodeling (LVAR) triggered upon myocardial infarction is recognized as the predominant pathological process in the development of heart failure. In the present study, we sought to investigate whether visit-to-visit fasting plasma glucose (FPG) variability is a potential predictor of LVAR in T2DM patients after STEMI.
METHODS
From January 2014 to December 2018 in Ruijin Hospital, T2DM patients with STEMI who underwent primary percutaneous coronary intervention were consecutively enrolled and followed up for ~ 12 months. The changes in left ventricular geometric and functional parameters between baseline and 12-month follow-up were assessed by echocardiography. The incidence of LVAR, defined as 20% increase in indexed left ventricular end-diastolic volume (LVEDV), and its relationship with visit-to-visit FPG variability were analyzed. Multivariate regression models were constructed to test the predictive value of FPG variability for post-infarction LVAR.
RESULTS
A total of 437 patients with type 2 diabetes and STEMI were included in the final analysis. During a mean follow-up of 12.4 ± 1.1 months, the incidence of LVAR was 20.6% and mean enlargement of indexed LVEDV was 3.31 ± 14.4 mL/m
CONCLUSIONS
This study suggests that visit-to-visit FPG variability is an independent predictor of incidence of LVAR in T2DM patients with STEMI. Trial registration Trials number, NCT02089360; registered on March 17,2014.
Identifiants
pubmed: 32878604
doi: 10.1186/s12933-020-01112-6
pii: 10.1186/s12933-020-01112-6
pmc: PMC7469406
doi:
Substances chimiques
Biomarkers
0
Blood Glucose
0
Banques de données
ClinicalTrials.gov
['NCT02089360']
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
131Références
Circulation. 2002 Sep 3;106(10):1251-5
pubmed: 12208801
Diabetologia. 2004 Feb;47(2):325-30
pubmed: 14722653
Clin Sci (Lond). 2011 Dec;121(12):555-64
pubmed: 21729007
Diabetes Metab. 2016 Nov;42(5):342-350
pubmed: 26971835
Eur Heart J Acute Cardiovasc Care. 2016 Oct;5(6):455-462
pubmed: 26228449
Hypertension. 2003 Dec;42(6):1206-52
pubmed: 14656957
Nat Rev Dis Primers. 2019 Jun 6;5(1):39
pubmed: 31171787
Eur J Heart Fail. 2012 Feb;14(2):185-92
pubmed: 21965526
Atherosclerosis. 2010 Jun;210(2):516-20
pubmed: 20083247
J Diabetes Complications. 2007 Sep-Oct;21(5):294-9
pubmed: 17825753
Diabetes Care. 2012 Jan;35 Suppl 1:S11-63
pubmed: 22187469
Diabetes Care. 2019 Mar;42(3):486-493
pubmed: 30659073
Kardiol Pol. 2014;72(1):20-6
pubmed: 23990231
Cardiovasc Diabetol. 2013 Jan 02;12:1
pubmed: 23280391
Biochem Pharmacol. 2012 Oct 1;84(7):961-73
pubmed: 22796564
JAMA. 1979 May 11;241(19):2035-8
pubmed: 430798
Diabetes Care. 2014 Aug;37(8):2359-65
pubmed: 24812434
Diabetol Metab Syndr. 2014 Jun 30;6:76
pubmed: 25013458
Diabetes Care. 2001 Aug;24(8):1422-7
pubmed: 11473080
Diabetes. 2003 Nov;52(11):2795-804
pubmed: 14578299
Circ J. 2015;79(5):1092-9
pubmed: 25739857
J Am Coll Cardiol. 2003 Jul 2;42(1):165-72
pubmed: 12849678
Circulation. 2004 Oct 5;110(14):1974-9
pubmed: 15451792
Circulation. 1990 Apr;81(4):1161-72
pubmed: 2138525
Diabetologia. 2009 May;52(5):952-61
pubmed: 19263033
Ann Intern Med. 2009 May 5;150(9):604-12
pubmed: 19414839
Cardiovasc Diabetol. 2018 Feb 24;17(1):33
pubmed: 29477146
Diabetes Care. 2018 Oct;41(10):2187-2194
pubmed: 30082325
Eur Heart J. 1999 Jul;20(13):973-8
pubmed: 10361050
Cardiovasc Diabetol. 2019 Apr 16;18(1):50
pubmed: 30992008
Diabetes Metab Res Rev. 2006 May-Jun;22(3):198-203
pubmed: 16453381
Cardiovasc Diabetol. 2019 Aug 7;18(1):100
pubmed: 31391045
Circulation. 2002 Oct 29;106(18):2351-7
pubmed: 12403666
Cardiovasc Diabetol. 2019 Mar 11;18(1):27
pubmed: 30857532
Eur J Heart Fail. 2009 Oct;11(10):911-21
pubmed: 19789393
Mayo Clin Proc. 2013 Sep;88(9):930-41
pubmed: 24001485
Cardiovasc Diabetol. 2019 Dec 5;18(1):166
pubmed: 31805945